|
1
|
Jacobs BL, Lee CT and Montie JE: Bladder
cancer in 2010: how far have we come? CA Cancer J Clin. 60:244–272.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gu FL and Liu YL: Changing status of
genitourinary cancer in recent 50 years. Chin J Urol. 2002:88–90.
2002.
|
|
3
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
|
|
4
|
Montie JE, Clark PE, Eisenberger MA, et
al: Bladder cancer. J Natl Compr Canc Netw. 7:8–39. 2009.
|
|
5
|
Wasco MJ, Daignault S, Zhang Y, et al:
Urothelial carcinoma with divergent histologic differentiation
(mixed histologic features) predicts the presence of locally
advanced bladder cancer when detected at transurethral resection.
Urology. 70:69–74. 2007. View Article : Google Scholar
|
|
6
|
Zhang M, Tao R, Zhang C and Shen Z:
Lymphovascular invasion and the presence of more than three tumors
are associated with poor outcomes of muscle-invasive bladder cancer
after bladder-conserving therapies. Urology. 76:902–907. 2010.
View Article : Google Scholar
|
|
7
|
Vicente-Manzanares M, Ma X, Adelstein RS
and Horwitz AR: Non-muscle myosin II takes centre stage in cell
adhesion and migration. Nat Rev Mol Cell Biol. 10:778–790. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Arii J, Goto H, Suenaga T, et al:
Non-muscle myosin IIA is a functional entry receptor for herpes
simplex virus-1. Nature. 467:859–862. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Simons M, Wang M, McBride OW, et al: Human
nonmuscle myosin heavy chains are encoded by two genes located on
different chromosomes. Circ Res. 69:530–539. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Burt RA, Joseph JE, Milliken S, Collinge
JE and Kile BT: Description of a novel mutation leading to
MYH9-related disease. Thromb Res. 122:861–863. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Conti MA and Adelstein RS: Nonmuscle
myosin II moves in new directions. J Cell Sci. 121:11–18. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Maeda J, Hirano T, Ogiwara A, et al:
Proteomic analysis of stage I primary lung adenocarcinoma aimed at
individualisation of postoperative therapy. Br J Cancer.
98:596–603. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Minamiya Y, Nakagawa T, Saito H, et al:
Increased expression of myosin light chain kinase mRNA is related
to metastasis in non-small cell lung cancer. Tumour Biol.
26:153–157. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xia ZK, Yuan YC, Yin N, Yin BL, Tan ZP and
Hu YR: Nonmuscle myosin IIA is associated with poor prognosis of
esophageal squamous cancer. Dis Esophagus. Sep 23–2011.(Epub ahead
of print). View Article : Google Scholar
|
|
15
|
Richards KL, Zhang B, Sun M, et al:
Methylation of the candidate biomarker TCF21 is very frequent
across a spectrum of early-stage nonsmall cell lung cancers.
Cancer. 117:606–617. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dyrskjøt L, Kruhøffer M, Thykjaer T, et
al: Gene expression in the urinary bladder: a common carcinoma in
situ gene expression signature exists disregarding
histopathological classification. Cancer Res. 64:4040–4048.
2004.
|
|
17
|
Sanchez-Carbayo M, Socci ND, Lozano J,
Saint F and Cordon-Cardo C: Defining molecular profiles of poor
outcome in patients with invasive bladder cancer using
oligonucleotide microarrays. J Clin Oncol. 24:778–789. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Botteman MF, Pashos CL, Redaelli A, Laskin
B and Hauser R: The health economics of bladder cancer: a
comprehensive review of the published literature.
Pharmacoeconomics. 21:1315–1330. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chen W, Luo JH, Hua WF, et al:
Overexpression of EIF-5A2 is an independent predictor of outcome in
patients of urothelial carcinoma of the bladder treated with
radical cystectomy. Cancer Epidemiol Biomarkers Prev. 18:400–408.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Schrier BP, Hollander MP, van Rhijn BW,
Kiemeney LA and Witjes JA: Prognosis of muscle-invasive bladder
cancer: difference between primary and progressive tumours and
implications for therapy. Eur Urol. 45:292–296. 2004. View Article : Google Scholar
|
|
21
|
Ridley AJ, Schwartz MA, Burridge K, et al:
Cell migration: integrating signals from front to back. Science.
302:1704–1709. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Dulyaninova NG, House RP, Betapudi V and
Bresnick AR: Myosin-IIA heavy-chain phosphorylation regulates the
motility of MDA-MB-231 carcinoma cells. Mol Biol Cell.
18:3144–3155. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Medjkane S, Perez-Sanchez C, Gaggioli C,
Sahai E and Treisman R: Myocardin-related transcription factors and
SRF are required for cytoskeletal dynamics and experimental
metastasis. Nat Cell Biol. 11:257–268. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liang S, He L, Zhao X, et al: MicroRNA
let-7f inhibits tumor invasion and metastasis by targeting MYH9 in
human gastric cancer. PLoS One. 6:e184092011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Derycke L, Stove C, Vercoutter-Edouart AS,
et al: The role of non-muscle myosin IIA in aggregation and
invasion of human MCF-7 breast cancer cells. Int J Dev Biol.
55:835–840. 2011. View Article : Google Scholar : PubMed/NCBI
|
